Roche Won’t Match NICE's Excessive Discount Expectations For Kadcyla
This article was originally published in The Pink Sheet Daily
Executive Summary
A discount and even the fulfilment of end-of-life criteria have failed to save Kadcyla at NICE, putting the struggle between health systems’ sustainability and the need for R&D plus innovation in the spotlight.